



Limitless Growth



DHARMAJ[®]
CROP GUARD LIMITED

Dharmaj Crop Guard Limited
FY23 Investor Presentation | May 2023



Inside

02-08

**Introduction
to Dharmaj**

02

**Unique Business
Model Positioning**

09

**Key
Takeaways**

24

**Annual Financial
Highlights**

27

**Quarterly Performance
Highlights**

32

Executive summary



One of the fastest growing agrochemicals player
40% 4Y Revenue CAGR
60% 4Y PAT CAGR



Capital efficient business model
32% 4Y Average ROCE
28% 4Y Average ROE



Backward integration to mark presence across value-chain



Reaching a meaningful size to capture next level of opportunities



Agile and growth-oriented organization structure



Well-capitalized financial structure
Comfortable D/E of 0.16 times

Company overview



Incorporated in 2015 by **multi-decade experienced industry professionals** (1st gen. promoters with agrochemicals & farming background)

Began with commercial operations & agrochemical **formulation manufacturing in 2016**

Core purpose: To provide radical solutions to human beings in such a way that they can grow with full potential and improve their prosperity.

Currently engaged in manufacturing and marketing agrochemical formulations, across broadly two verticals:

- **Branded (B2C)**
- **Institutional (B2B)**

Upcoming Active Ingredients manufacturing facility at Sayakha to integrate the Company's business model across the value chain



VISION

We are a market-focused, process centred organization that develops and delivers innovative solutions to our customers. Our main aim is to be the most trusted and ethical source of our products across the globe.



Organisational goal set by founding team during incorporation

Become a ₹2,000 Crore Company by 2030

Company in numbers



Domestic Presence

13,500+

Retail touchpoints



Institutional Base

730+

Customer base



Manufacturing Infrastructure

25,500 MT

Formulations Capacity



Product Registrations

490

Total Product Registrations



Others

325+

Team Strength

4,500+

Dealers & distributors

Customer base spanning

26

countries

8,000 MT

Upcoming Technicals & Intermediates Capacity

200

Export Product Registrations

190+

On-ground Sales Force

Present in

20 states

with **16 stock depots**

230+

Products in institutional portfolio


10

Technicals Registrations Received, **14** Under Registration

CRISIL BBB

Credit rating upgraded to **CRISIL BBB/ Stable/CRISIL A3+** recently

Establish. Build. Expand.



Board of Directors

Board of Directors Personnel



1 Mr. Rameshbhai Ravajibhai Talavia
Chairman and Managing Director



2 Mr. Jamankumar Hansarajbhai Talavia
Whole Time Director



3 Mr. Jagdishbhai Ravjibhai Savaliya
Whole Time Director



4 Mr. Deepak Bachubhai Kanparia
Independent Director



5 Mr. Bhaveshkumar Jayantibhai Ponkiya
Independent Director



6 Ms. Amisha Fenil Shah
Independent Director







25+ years

Of average promoter and management expertise

- Possesses nearly 3 decades of experience in the agrochemical industry.
 - Holds a bachelor's degree in agriculture.
 - Leads the overall business strategy of the Company.
- Possesses nearly 3 decades of experience in the agrochemical industry.
 - Holds a bachelor's degree in Science (Agriculture) from Gujarat Agricultural University.
 - Heads the manufacturing & purchase function of the Company.
- Possesses over 21 years of work experience.
 - Holds a bachelor's in Science from Saurashtra University.
 - Heads the research & development and production function of the Company.
- Possesses over 3 decades of experience in the agro-marketing field.
 - Holds a bachelor's in Technology (Agriculture Engineering) from Gujarat Agriculture University and a diploma in Computer Applications from Data Tech.
- Possesses over 8 years of experience in audit and taxation.
 - He a Chartered Accountant and a member of ICAI, and holds a bachelor's degree in Commerce and Law from the Gujarat University.
- Possesses over 6 years of experience in secretarial matters.
 - Holds a bachelor's degree in Commerce from the Gujarat University, bachelors' degree in law from Gujarat University and is a member of ICSI.

Management Team

Key Management Personnel

- 1  **Mr. Rameshbhai Ravajibhai Talavia**
Chairman and Managing Director
- 2  **Mr. Vishal Domadia**
Chief Executive Officer
- 3  **Mr. Vinay Joshi**
Chief Financial Officer
- 4  **Ms. Malvika Bhadreshbhai Kapasi**
Company Secretary and Compliance Officer







1 **Work Experience:**
30+ years
Ex: Coromandel International, Crop Life Science

2 **Work Experience:**
14+ years
Ex: Excel Crop Care, Cheminova India, Sumitomo India, Crop Life Science

3 **Work Experience:**
25+ years
Ex: Akar Auto Industries, IRM (Cadila Pharma Group), Karvy Comtrade, Satyam Computers, Panasonic India, Gemstone Glass

4 **Work Experience:**
6+ years
Ex: Kayel Securities, Ideal Systems and S.S.B.I. Exports

Senior Management Personnel

- 5  **Mr. Bhupendra Varasada**
Head of Operations – Sayakha Unit
 - 6  **Mr. Hitesh Patel**
Vice President – Marketing
 - 7  **Mr. Mahesh Raghavan Vellichiramallinella**
Deputy General Manager – Exports
 - 8  **Mr. Jitendra Modha**
Deputy General Manager - Quality
 - 9  **Mr. Kalpesh C. Patel**
Senior Manager Accounts
 - 10  **Mr. Mehulkumar H. Polara**
Manager – Institutional Sales
- 5 **Work Experience:**
32+ years
Ex: Sabero Organic, Heranba Industries, UPL, Hemani Industries
 - 6 **Work Experience:**
19+ years
Ex: BASF India, Monsanto India, Bayer Crop Science, SML Group
 - 7 **Work Experience:**
32+ years
Ex: Meghmani Organics
 - 8 **Work Experience:**
28+ years
Ex: Sabero Organics
 - 9 **Work Experience:**
15+ years
Ex: Jyoti Power Corporation, Elitecore Technologies, Jaihind Projects
 - 10 **Work Experience:**
13+ years
Ex: Bayer India, Excel Crop Care, Akshay Seed Tech Co.



Inside

09-23

Introduction
to Dharmaj

02

**Unique Business
Model Positioning**

09

Key
Takeaways

24

Annual Financial
Highlights

27

Quarterly Performance
Highlights

32

Expanding presence in value chain

Technicals & Intermediates
Manufacturing:
Upcoming Facility

8,000 TPA Capacity
coming on-stream
in Q3FY24

Integrated for key
Intermediates

Formulations
Manufacturing

**25,500 TPA Integrated
Capacity** (expanded
recently in FY22)

Marketing:
B2C & B2B

B2C: Growing distribution
network spanning **20 states**
& **13,500 touchpoints**

B2B: Actively built working
relationships with entire AgChem
industry in past 8 years

Expanding presence
across the value chain:
the way forward for Dharmaj



Improvement in blended
margin profile with Active
Ingredients operations

Will strengthen existing
formulations business:
both B2B & B2C

Will improve **cost-
competitiveness** thereby open-
up export markets in a big way

Will open up
**opportunities in Public
& Animal Health** vertical

Business model: pursuing growth on all fronts

	SIZE	REVENUE CONTRIBUTION	PROFITABILITY PROFILE	GROWTH TREND	GEOGRAPHY
Branded Formulations	<p>₹1,448 mn Revenue</p>	 <p>27%</p>	<p>GPM 30-35%</p> <p>EBITDA 14-16%</p>	<p>Branded Formulations 4Y 33% Revenue CAGR</p>	<p>Domestic branded business across 20 states</p>
Institutional Formulations	<p>₹3,287 mn Revenue</p>	 <p>73%</p>	<p>GPM 15-20%</p> <p>EBITDA 10-11%</p>	<p>Domestic Institutional 4Y 44% Revenue CAGR</p> <p>Export Institutional 4Y 39% Revenue CAGR</p>	<p>Domestic Institutional Business 62% of Sales</p> <p>Exports Institutional Business 11% of Sales</p>
Active Ingredients	<p>Revenue contribution to begin post plant commissioning</p>		<p>GPM 28-32%</p> <p>EBITDA* 20%+</p>		<p>To engage in both domestic & export trade for Active Ingredients</p>

Note: Active Ingredients profitability margins as per internal estimates & projections on optimum capacity utilisation, and Branded & Institutional Formulations profitability numbers as per internal estimates based on last 5Y trend.

*Note – EBITDA (%) at optimum capacity utilization. Exports Institutional Business also includes merchant exports done by the Company.

Branded formulations (1/5)

Initial strategy



- 1 Entering 2 new states on an average every year since incorporation, following a clustered growth approach
- 2 Strict focus on trade receivables & cash conversion
- 3 Competitive aggression in pricing and not in credit period
- 4 Innovative trade policies to deliver aggressive growth while adhering to working capital discipline
- 5 Aggressive ground-level marketing, demand generation, and brand building
- 6 Recently entered 6 states in 2022 to step-up growth: Uttar Pradesh, Punjab, Haryana, Uttarakhand, Jammu & Kashmir and Maharashtra

Distribution built in last 8 years

13,500 +
Retail touchpoints


4,500 +
Dealers & Distributors

20
States

16
Stock Depots

Branded Formulation Sales Trend (₹ Mn)

▲ 33% CAGR



Branded formulations (2/5)

Aggressive demand generation & brand building

Proactive with on-ground demand generation, stakeholder engagement and brand building:



Proactive Dealer Appointments



Regular Farmer Meetings



Organising Field Days



Conducting Field Visits



Organising Product Demonstrations




Jeep campaigns



Expansion of Sales Force


Growing Thrust On Advertisement & Sales Promotion Expenditure

(₹ Mn)



Growing On-ground Sales & Marketing Team

(#)



Branded formulations (3/5)

Robust brand portfolio

■ Latest Additions: Insecticides
 ■ Latest Additions: Herbicides
 ■ Best Selling Brands




121+
Products
 350+
SKUs

Product Innovation Index

Contribution from Newly Launched Products (CY & PY launches) & New Product Launches

(% and #)



▶ **New products, combinations, and brand launches** to maintain overall profitability of the portfolio


▶ **Product launches** a continuous function

Key Launches in Last 3 Years:

- | FY23 | FY22 | FY21 |
|---|---|---|
| <ul style="list-style-type: none"> • Anteem • Dharrise • Suristar • Regiment • Pendiza | <ul style="list-style-type: none"> • Zeekasulf • Dhargor • Parthav • Jojil • Mosam | <ul style="list-style-type: none"> • Dahaad • Sadavirum • Kohha • Kawayat • Super • Lisoton |

Branded formulations (4/5)

Clustered expansion



□ Presences

Future Focus Areas

Strengthening position is existing markets

- Example: establishing ourselves amongst top 5 branded players by sales in Gujarat
- Working to replicate this across other states over time

Expanding into newer markets, becoming a pan-India player

20 states covered so far, after adding 6 recently in 2022



Adding new products, formulation combinations, and refreshing portfolio to maintain overall profitability

Achieving scale to tap next level of opportunities:

Begin move towards tie-ups with global innovators, in-licensed marketing model

Branded formulations (5/5)

Leveraging technology to strengthen business:



Institutional formulations (1/3)




Marquee clients



- 1 Institutional formulations business is the biggest revenue vertical for the Company since incorporation
- 2 Formulations marketed in all kinds of packaging to B2B customers in India and abroad
- 3 Actively engaging with small formulators & regional players (<10 Cr sales): **an underserved category**
- 4 Offering 230+ products to 730+ customers of all sizes: MNCs, domestic majors, and smaller firms
- 5 Exports to 70+ institutional customers across 26 countries

Domestic Formulation Sales Trend (₹ Mn)

▲ 44% CAGR



Export Formulation Sales Trend (₹ Mn)

▲ 39% CAGR



Note: Exports Formulations Sales also includes Merchant Exports

Institutional formulations (2/3)

Our product portfolio



Insecticide

Fipronil 40% +
Imidacloprid 40% WG
(Bulk)

Emamectin Benzoate
5% SG (Bulk)

Acetamiprid 20% SP
(Bulk)

Chlorpyrifos
Technical

Chlorpyrifos 50% +
Cypermethrin 5% EC
(Bulk)



Herbicides

Paraquate Dichloride
Technical

Glyphosate Technical

2,4-D Amine Salt 58%
SL (Bulk)

Glyphosate 41% SL
(Bulk)

Metribuzin 75% WG
(Bulk)



Fungicides

Carbendazim 12% +
Mancozeb 63% WP
(Bulk)

Cymoxanil 8% +
Mancozeb 64% WP (Bulk)

Azoxystrobin Technical

Azoxystrobin 11% +
Tebuconazole 18.3% SC
(Bulk)

Mancozeb 80% WP -
Yellow (Bulk)



Micro-Fertilizers

Sulphur 65% + Zinc
18% (Bulk)

Sulphur 90% GR (Bulk)

Boron 20% (Bulk)

Zinc 12% EDTA (Bulk)



Plant Growth Regulator

Gibberellic Acid
Technical

Ethephon 39% SL (Bulk)

Silicon Adjuvent (Bulk)

Hexythiazox
Technical

Institutional formulations (3/3)

Future focus areas

200
export market
products
registered

**Currently active
in 5-7 markets.**

**Plans to expand
in more
countries.**

Domestic Institutional

Backward integration into active ingredients to strengthen cost-competitiveness

More engagement with MNC customers post backward integration, initial orders executed with some groups

Exports Institutional

Ramp-up export market product registration efforts & investments

Expecting initial registrations to flow from certain African, Latin American, and select developed markets in the coming year

Export business to increase dramatically as backloaded product registrations come in

Efforts to grow beyond existing export markets and increase long-tail

15
product
registrations
under process

Active Ingredients (1/3)

Foraying into **Technicals & Intermediates manufacturing**

through its upcoming greenfield facility at Sayakha

Synthetic Pyrethroids

will be the initially targeted product basket

Key technicals (7-8):

- Deltamethrin
- Lambda Cyhalothrin
- Bifenthrin
- Alphamethrin
- Cypermethrin

Key intermediates:

- MPBD
- CMAC

3 separate production blocks:

2 dedicated intermediates manufacturing lines

1 multi-purpose technical manufacturing block


Ability to manufacture 6 technicals simultaneously over 3 lines

Facility being setup in accordance with **export market regulatory standards**

Dedicated R&D and QC laboratory with state-of-art equipment

Head of **R&D** appointed, team building ongoing

Active Ingredients Journey



Active Ingredients (2/3)

Manufacturing Capacity

- **2,500 TPA** dedicated MPBD capacity
- **2,500 TPA** dedicated CMAC capacity
- **3,000 TPA** cumulative, multipurpose technical capacity
- **8,000 TPA** Cumulative capacity

Project Financing

- IPO Proceeds: **₹105 Cr**
- Term Loans Sanctioned: **Up to ₹100 Cr**
- Short-term borrowings to finance working capital requirements
- Internal Accruals to be deployed in both CAPEX & Working Capital

• Potential ~3X

Fixed Asset Turns at Optimum Capacity Utilization & Product-Mix

Captive Consumption vs. External Sales

- **60-70%** captive consumption for intermediates
- **20-25%** captive consumption for technicals

Process Optimisations


- Latest generation P&M opted for higher overall efficiency
- Improvement in solvent recovery
- Improvement in distillation process to achieve better yields & purity

Why Synthetic Pyrethroids?

- Open up Public & Animal Health vertical for the Company
- Confident of technical learning curve & plant stabilisation in this product group
- Complementary product profile to existing formulation business
- India strengthening its position as an export hub of Synthetic Pyrethroids
- High potential use in Public Health & Animal Health



Total Estimated Capital Outlay (%)



Note: ~3X Asset Turns at Optimum Capacity assumes 100% external sales of output manufactured at the Sayakha plant, however, the Company will consume a part of the production as feedstock for formulations vertical.

Active Ingredients (3/3)

Status as of early April



**R&D and
Administration Block**



**Furniture Work at R&D Laboratory
and Administration Office**



**Reactor
Installation**



**Technicals Block (Left Side)
Intermediates Block (Centre)**



**Material Storage
Facilities**



**Reactors Installed &
Piping Commenced**

Formulation Manufacturing Facility

Fully integrated formulation facility

All formulations categories manufactured – **EC, SC, SL, SG, WDG, WP, DP, GR, CS, ZC**

Equipped with bio reactor to treat waste / sewage water to remove pollutants


Located at **Kerala GIDC, Ahmedabad**

Equipped with solar power plant of **85,320 KW annual capacity**

Equipped with STP of **7,800 KL capacity**



25,500 MT
Manufacturing Capacity




50%
Blended FY23 Capacity Utilisation



R&D
centre at site
QC laboratory at site

Manufacturing Capacity
(in MT)



Certifications



Note – Higher formulation capacity built for catering peak H1 season demand.



Inside

24-25

Introduction
to Dharmaj

02

Unique Business
Model Positioning

09

**Key
Takeaways**

24

Annual Financial
Highlights

27

Quarterly Performance
Highlights

32

Key Takeaways



Keep up the pace of growth as witnessed in past: double topline every three years, pursue growth in all business verticals



Leverage potential of newly entered states in branded formulations, while strengthening position in existing markets



Build export institutional business with growing product registrations efforts, to reap backloaded results. Enter high-potential markets.



Targeting **new set of opportunities with scale:** licensed formulation marketing, tie-ups with international players, among others



Make a successful entry into active ingredients, stabilize plant, and achieve capacity utilization targets (3 years to fully utilize plant)



A background image of a financial candlestick chart with green and red bars, overlaid with a white rounded rectangle containing the word 'Inside' and a large white number '27-31'.

Inside

27-31

Introduction
to Dharmaj

02

Unique Business
Model Positioning

09

Key
Takeaways

24

Annual Financial
Highlights

27

Quarterly Performance
Highlights


32

Key Performance Indicators

Revenue from Operations

(₹ Mn)


▲ 40% CAGR



EBITDA & EBITDA Margin


(₹ Mn & %)

▲ 46% CAGR



Cash Conversion Cycle


(Days)



ROCE & ROE

(%)


● ROCE ● ROE



Total Equity & Debt to Equity

(₹ Mn & Times)

■ Total Equity ● Debt to Equity



Net Block & Fixed Asset Turns

(₹ Mn & Times)

■ Net Block ● Fixed Asset Turns



Note: ROCE & ROE dipped in FY23 due to higher denominator i.e., Capital Employed & Equity, due to the IPO in Dec-22

Note: Equity is significantly higher in FY23 due to the IPO in Dec-22

Profit & Loss Summary (5Y)

(₹ Mn)

Particulars	FY19	FY20	FY21	FY22	FY23
Revenue from Operations	1,394	1,982	3,024	3,942	5,336
Total Income	1,400	1,992	3,036	3,963	5,381
Gross Profit	285.90	428.55	630.05	799.32	955.76
Gross Profit Margin (%)	21%	22%	21%	20%	18%
Operating Expenses	181	249	319	356	482
EBITDA (Excluding OI & EI)	105	179	311	443	474
EBITDA Margin (%)	8%	9%	10%	11%	9%
Finance Cost	21	22	14	26	23
Depreciation & Amortisation	20	22	26	53	51
Profit Before Taxes (and EI)	70	145	282	385	445
Profit After Taxes	50	108	210	287	331
Profit After Taxes Margin (%)	3.59%	5.40%	6.90%	7.24%	6.15%
Earnings Per Share (₹)*	5.02	8.62	12.74	11.62	12.03

Note: *EPS not annualised

Balance Sheet Summary (5Y)

(₹ Mn)

Particulars	FY19	FY20	FY21	FY22	FY23
TOTAL EQUITY	105	354	563	849	3,214
Non-Current Liabilities	181	65	173	280	378
Borrowings	172	51	152	253	335
Current Liabilities	190	506	552	1,067	792
Borrowings	32	151	117	116	189
Trade Payables	129	332	391	914	553
TOTAL EQUITY & LIABILITIES	477	926	1,289	2,195	4,385
Non-Current Assets	144	309	458	658	1,514
Property, plant and equipment	116	217	387	389	385
Capital work-in-progress	-	23	11	177	947
Current Assets	333	617	830	1,538	2,871
Inventories	153	276	436	629	729
Trade Receivables	170	333	362	860	741
Cash and cash equivalents	8	3	10	10	4
TOTAL ASSETS	477	926	1,289	2,195	4,385

Cash Flow Summary (5Y)

(₹ Mn)

Particulars	FY19	FY20	FY21	FY22	FY23
Cash from Operating Activities	33	20	129	164	(74)
Cash from Investing Activities	(40)	(146)	(177)	(239)	(2,073)
Cash from Financing Activities	4	121	55	75	2,142
Net Cash Flow	(3)	(5)	7	(0)	(5)
Cash at Beginning of Year	11	8	3	10	10
Cash at End of Year	8	3	10	10	4



Inside

32-33

Introduction
to Dharmaj

02

Unique Business
Model Positioning

09

Key
Takeaways

24

Annual Financial
Highlights

27

Quarterly Performance
Highlights

32

Profit & Loss Summary (Q4)

(₹ Mn)

Particulars	Q4FY22	Q3FY23	Q4FY23	YoY Change	FY22	FY23	YoY Change
Revenue from Operations	1,013	1,011	737	-27%	3,942	5,336	35%
Total Income	1,023	1,016	767	-25%	3,963	5,381	36%
Gross Profit	160	202	173	8%	799	956	20%
Gross Profit Margin (%)	16%	20%	23%	764 BPS	20%	18%	-236 BPS
Operating Expenses	115	115	167	45%	356	482	35%
EBITDA (Excluding OI & EI)	45	87	6	-88%	443	474	7%
EBITDA Margin (%)	4%	9%	1%	-83%	11%	9%	-21%
Finance Cost	9	7	4	-60%	26	23	-11%
Depreciation & Amortisation	14	12	15	10%	53	51	-4%
Profit Before Taxes (and EI)	32	74	18	-45%	385	445	15%
Profit After Taxes	23	55	12	-47%	287	331	15%
Profit After Taxes Margin (%)	2.30%	5.41%	1.63%	-29%	7.24%	6.15%	-15%
Earnings Per Share (₹)*	0.95	1.63	0.45		11.62	12.03	

Note: *EPS not annualised

Management Commentary

FY23 ended as a good year for the Company despite multiple macro challenges within the agrochemical industry. Amidst all the headwinds within the industry, the Company managed to deliver a robust 35% annual sales growth, coupled with 15% net profit growth during the year. H2 ended-up being a challenging period, where several industry-level challenges such as destocking of supply chains, steep fall in prices of inputs & agrochemical products led to a standstill within the industry. On the Company level, we witnessed an average 25% reduction in price realisations in the last 5 months, which has led to degrowth in H2FY23 compared to the corresponding period in previous year, despite registering slightly higher sales volumes.

The new season for the domestic business, which typically starts around mid-March for DCGL, seems to be delayed by a month as we witnessed slower offtake in April. We are hopeful of better offtake with the onset of the new monsoon as the buying for the upcoming season kicks in.

Further, we are excited about our Branded business for the upcoming year, as the Company has tapped six new states last year where we will be operating for the first full season in H1FY24. These states will be a major driver for the Branded vertical in the coming year. On the institutional side, the Company has started initial business with some larger accounts as well, and we expect these relationships to scale up as we expand across active ingredients. We are also anticipating higher business on the exports front this year, on the back of product registrations and entry into new markets.

The work at the Sayakha Unit is going on at a brisk pace. After the completion of civil works, the team at the site has almost finished reactor installation in the intermediates block and will take up the Technicals block next. We are on track to commercialise this facility in Q3FY23. The R&D laboratory at the Sayakha unit is expected to start in June 2023. We have already appointed the head of the R&D function at Sayakha and are in the process of building the rest of the team. This team will be working on process research for our initial product basket, helping the Company optimise yields, achieve better process efficiency, and overall productivity.

As we enter the new financial year, we look forward to growth on all fronts i.e., our existing branded & institutional formulations business, while commencing our upcoming active ingredients business.




We are on track to begin commercial production at Sayakha Unit by Q3FY24. This facility will mark our entry into technical & intermediates manufacturing, which will be instrumental in our next leg of growth.

Mr. Rameshbhai Ravajibhai Talavia
Chairman and Managing Director

Shareholding & Market Statistics

NSE Symbol	<u>DHARMAJ</u>
BSE Scrip Code	<u>543687</u>
IPO Issue Price Band	₹216 to ₹237
Current Market Price	₹181
52 Week High/Low	₹279 / ₹137
Shares Outstanding	3.38 Cr
Market Capitalization	₹612 Cr
Industry Classification	Pesticides & Agrochemicals



Note: Data as on 15 May 2023

Safe Harbour

This document which have been prepared by Dharmaj Crop Guard Limited (the "Company"), have been prepared solely for information purposes. This document has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Document. This Document may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Document is expressly excluded.

Certain matters discussed in this Document may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Document. The Company assumes no obligation to update any forward-looking information contained in this Document. Any forward-looking statements and projections made by third parties included in this Document are not adopted by the Company and the Company is not responsible for such third-party statements and projections.



DHARMAJ CROP GUARD LIMITED

Mr. Vinay Joshi

Chief Financial Officer

cfo@dharmajcrop.com

079 2960 3735

W: www.dharmajcrop.com



TIL ADVISORS PRIVATE LIMITED

Investor Relations Advisor

Mr. Sayam Pokharna

Director

sayam@theinvestmentlab.in

+91 94266 60791